Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
144.70
+3.50 (2.48%)
Jun 6, 2025, 4:00 PM - Market closed
CRL Revenue
Charles River Laboratories International had revenue of $984.17M in the quarter ending March 29, 2025, a decrease of -2.71%. This brings the company's revenue in the last twelve months to $4.02B, down -2.16% year-over-year. In the year 2024, Charles River Laboratories International had annual revenue of $4.05B, down -1.92%.
Revenue (ttm)
$4.02B
Revenue Growth
-2.16%
P/S Ratio
1.84
Revenue / Employee
$200,129
Employees
20,100
Market Cap
7.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 28, 2024 | 4.05B | -79.42M | -1.92% |
| Dec 30, 2023 | 4.13B | 153.35M | 3.86% |
| Dec 31, 2022 | 3.98B | 435.90M | 12.31% |
| Dec 25, 2021 | 3.54B | 616.23M | 21.08% |
| Dec 26, 2020 | 2.92B | 302.71M | 11.55% |
| Dec 28, 2019 | Pro | Pro | Pro |
| Dec 29, 2018 | Pro | Pro | Pro |
| Dec 30, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 26, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
CRL News
- 6 days ago - Charles River Laboratories to Present at William Blair and Jefferies Conferences - Business Wire
- 11 days ago - Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington's Disease Research - Business Wire
- 26 days ago - Charles River Laboratories to Present at Bank of America Health Care Conference - Business Wire
- 4 weeks ago - Activist Elliott reaches key agreement with Charles River. Here are three ways to create value - CNBC
- 4 weeks ago - S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments - Investopedia
- 4 weeks ago - Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization - Benzinga
- 4 weeks ago - Charles River Stock Is Having Its Best Day in 13 Years. A Board Shake-Up and Business Review Will Help. - Barrons